Generic Ponvory Availability
Last updated on Apr 10, 2025.
Ponvory is a brand name of ponesimod, approved by the FDA in the following formulation(s):
PONVORY (ponesimod - tablet;oral)
-
Manufacturer: VANDA PHARMS INC
Approval date: March 18, 2021
Strength(s): 2MG [RLD], 3MG [RLD], 4MG [RLD], 5MG [RLD], 6MG [RLD], 7MG [RLD], 8MG [RLD], 9MG [RLD], 10MG [RLD], 20MG [RLD]
Is there a generic version of Ponvory available?
No. There is currently no therapeutically equivalent version of Ponvory available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ponvory. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dosing regimen for a selective S1Preceptor agonist
Patent 10,220,023
Issued: March 5, 2019
Inventor(s): Dingemanse Jasper & Hoch Matthias & Krause Andreas
Assignee(s): ACTELION PHARMACEUTICALS LTDThe present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.
Patent expiration dates:
- December 10, 2035✓
- December 10, 2035
-
Methods of treating multiple sclerosis
Patent 11,951,097
Issued: April 9, 2024
Inventor(s): DiBernardo; Allitia et al.
Assignee(s): Vanda Pharmaceuticals Inc. (Washington, DC)The disclosure relates to methods of treating multiple sclerosis. Also provided are pharmaceutical products containing ponesimod, instructions for use of ponesimod, methods for selling a drug product containing ponesimod, and methods for reducing clinical management events before or during treatment of multiple sclerosis.
Patent expiration dates:
- October 10, 2042✓
- October 10, 2042
-
Thiazolidin 4-one derivatives
Patent 8,273,779
Issued: September 25, 2012
Inventor(s): Binkert Christoph & Bolli Martin & Mathys Boris & Mueller Claus & Scherz Michael & Nayler Oliver
Assignee(s): Actelion Pharmaceuticals Ltd.The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.
Patent expiration dates:
- December 17, 2025✓
- December 17, 2025
-
Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
Patent 9,062,014
Issued: June 23, 2015
Inventor(s): Bonham Nicholas & Buchmann Stephan & Eberlin Alex & Imboden Christoph & Von Raumer Markus
Assignee(s): ACTELION PHARMACEUTICALS LTD.The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.
Patent expiration dates:
- May 6, 2032✓✓✓
- May 6, 2032
-
Thiazolidin-4-one derivatives
Patent RE43728
Issued: October 9, 2012
Inventor(s): Binkert Christoph & Bolli Martin & Mathys Boris & Mueller Claus & Scherz Michael & Nayler Oliver
Assignee(s): Actelion Pharmaceuticals Ltd.The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents.
Patent expiration dates:
- November 16, 2029✓✓
- November 16, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 18, 2026 - NEW CHEMICAL ENTITY
More about Ponvory (ponesimod)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
